-
Je něco špatně v tomto záznamu ?
Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine
R. Jorda, J. Dušek, E. Řezníčková, K. Pauk, PP. Magar, A. Imramovský, V. Kryštof,
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
Odkazy
PubMed
28441582
DOI
10.1016/j.ejmech.2017.04.027
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky chemická syntéza chemie farmakologie MeSH
- fenylalanin chemie farmakologie MeSH
- inhibitory proteasomu chemická syntéza chemie farmakologie MeSH
- léky antitumorózní - screeningové testy MeSH
- leucin chemie farmakologie MeSH
- lidé MeSH
- molekulární struktura MeSH
- nádorové buněčné linie MeSH
- proliferace buněk účinky léků MeSH
- proteasomový endopeptidasový komplex metabolismus MeSH
- salicylamidy chemická syntéza chemie farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Inhibition of protein degradation is one of strategies for suppression of uncontrolled proliferation of cancer cells. Proteolytic degradation in cells is mainly ensured by proteasome and its inhibition by bortezomib showed benefit in clinical use for the treatment of multiple myeloma. We report here the library of antiproteasomal O-benzyl salicylamides built from leucine and phenylalanine. Prepared compounds displayed antiproliferative activity on K562, CEM and U266 cancer cell lines, ranging from high micromolar to submicromolar GI50 values. The most potent compounds (series 4 and 6) were further assayed for their inhibition of chymotrypsin-like protease activity of the 26S proteasome in U266 cells. The majority of compounds inhibited the proteasome in mid-nanomolar concentrations (IC50 ranging from 57 to 197 nM) and it correlated with cellular potency. In a cell based assay involving green fluorescence protein (GFP) fused to a short degron that is rapidly degraded by a proteasome the compounds induced accumulation of GFP, visualised and quantified by live-cell imaging. Levels of polyubiquitinated proteins in U266 cells treated by compound 4m were also analyzed by immunoblotting, revealing a typical high molecular mass smear of ubiquitin conjugates. Finally, apoptotic cell death in treated U266 cells was detected biochemically by measuring the activity of caspases 3 and 7 in lysates and by immunoblotting of caspase 7, its substrate poly(ADP-ribose)polymerase, and Mcl-1, which all together showed changes typical for apoptosis. All these observations were in agreement with expected cellular mechanism of action and confirmed proteasome targeting by prepared O-benzyl salicylamides.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030861
- 003
- CZ-PrNML
- 005
- 20240612142433.0
- 007
- ta
- 008
- 171025e20170415fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2017.04.027 $2 doi
- 035 __
- $a (PubMed)28441582
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University & Institute of Experimental Botany ASCR, Šlechtitelů 27, 78371 Olomouc, Czech Republic.
- 245 10
- $a Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine / $c R. Jorda, J. Dušek, E. Řezníčková, K. Pauk, PP. Magar, A. Imramovský, V. Kryštof,
- 520 9_
- $a Inhibition of protein degradation is one of strategies for suppression of uncontrolled proliferation of cancer cells. Proteolytic degradation in cells is mainly ensured by proteasome and its inhibition by bortezomib showed benefit in clinical use for the treatment of multiple myeloma. We report here the library of antiproteasomal O-benzyl salicylamides built from leucine and phenylalanine. Prepared compounds displayed antiproliferative activity on K562, CEM and U266 cancer cell lines, ranging from high micromolar to submicromolar GI50 values. The most potent compounds (series 4 and 6) were further assayed for their inhibition of chymotrypsin-like protease activity of the 26S proteasome in U266 cells. The majority of compounds inhibited the proteasome in mid-nanomolar concentrations (IC50 ranging from 57 to 197 nM) and it correlated with cellular potency. In a cell based assay involving green fluorescence protein (GFP) fused to a short degron that is rapidly degraded by a proteasome the compounds induced accumulation of GFP, visualised and quantified by live-cell imaging. Levels of polyubiquitinated proteins in U266 cells treated by compound 4m were also analyzed by immunoblotting, revealing a typical high molecular mass smear of ubiquitin conjugates. Finally, apoptotic cell death in treated U266 cells was detected biochemically by measuring the activity of caspases 3 and 7 in lysates and by immunoblotting of caspase 7, its substrate poly(ADP-ribose)polymerase, and Mcl-1, which all together showed changes typical for apoptosis. All these observations were in agreement with expected cellular mechanism of action and confirmed proteasome targeting by prepared O-benzyl salicylamides.
- 650 _2
- $a antitumorózní látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a léky antitumorózní - screeningové testy $7 D004354
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leucin $x chemie $x farmakologie $7 D007930
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a fenylalanin $x chemie $x farmakologie $7 D010649
- 650 _2
- $a proteasomový endopeptidasový komplex $x metabolismus $7 D046988
- 650 _2
- $a inhibitory proteasomu $x chemická syntéza $x chemie $x farmakologie $7 D061988
- 650 _2
- $a salicylamidy $x chemická syntéza $x chemie $x farmakologie $7 D012457
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dušek, Jan $u Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic. $7 xx0318365
- 700 1_
- $a Řezníčková, Eva $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University & Institute of Experimental Botany ASCR, Šlechtitelů 27, 78371 Olomouc, Czech Republic.
- 700 1_
- $a Pauk, Karel $u Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic.
- 700 1_
- $a Magar, Pratibha P $u Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic.
- 700 1_
- $a Imramovský, Aleš $u Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic. Electronic address: Ales.Imramovsky@upce.cz.
- 700 1_
- $a Kryštof, Vladimír $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University & Institute of Experimental Botany ASCR, Šlechtitelů 27, 78371 Olomouc, Czech Republic. Electronic address: vladimir.krystof@upol.cz.
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 135 (20170415), s. 142-158
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28441582 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20240612142434 $b ABA008
- 999 __
- $a ok $b bmc $g 1254454 $s 991888
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 135 $c - $d 142-158 $e 20170415 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20171025